CYP2C19基因多态性与急性心肌梗死患者炎症指标、临床预后的相关性

doi:10.3969/j.issn.1000-8535.2022.01.001

摘要/Abstract

摘要： 目的探讨急性心肌梗死患者细胞色素P450酶基因(cytochrome P450,family 2,subfamily C,polypeptide 19,CYP2C19)多态性与高敏C-反应蛋白(hypersensitive C-reactive protein,hs-CRP)、白细胞介素-6(interleukin- 6,IL-6)及临床预后的相关性。方法选取2019年5月—2020年5月入住我院心血管内科的急性心肌梗死患者182例作为研究对象,研究对象均接受经皮冠脉介入术,采取RT-PCR方法进行外周全血CYP2C19基因多态性的检测,并进行分组。口服阿司匹林300 mg和氯吡格雷300 mg后次日,测定血中hs-CRP和IL-6含量,治疗后12个月内,随访主要心血管不良事件。结果 182例急性心肌梗死患者中,快代谢组(CYP2C19*1/*1)患者最多,为78例(42.8%);中等代谢组(CYP2C19*1/*2、CYP2C19*1/*3),为65例(35.7%);慢代谢型组(CYP2C19*2/*2、CYP2C19*2/*3、CYP2C19*3/*3)最少,为39例(21.5%)。与快代谢组比较,中代谢组及慢代谢组hs-CRP、IL-6水平均升高,差异有统计学意义(P<0.05);与中代谢组比较,慢代谢组患者hs-CRP、IL-6水平均升高,差异有统计学意义(P<0.05)。CYP2C19基因型与hs-CRP及IL-6呈正相关(r=0.163、0.175,P<0.05)。中代谢组、慢代谢组患者1年内主要心血管不良事件发生率高于快代谢组患者(P<0.05)。结论 CYP2C19基因型与hs-CRP及IL-6具有相关性,CYP2C19基因型为中代谢型和慢代谢型能够激活机体炎症反应,影响急性心肌梗死患者的临床预后。

关键词: 急性心肌梗死, CYP2C19, hs-CRP, IL-6, 预后

Abstract: Objective To explore the correlation of cytochrome P450 gene (CYP2C19) polymorphism with hypersensitive C-reaction protein (hs-CRP), interleukin-6 (IL-6) and prognosis in patients with acute myocardial infarction (AMI). Methods A total of 182 patients with AMI admitted to cardiology department from May 2019 to May 2020 were selected as the research objects, all subjects underwent percutaneous coronary intervention (PCI), and CYP2C19 gene polymorphism in peripheral blood was detected by RT-PCR, which was grouping basis. One day after taking aspirin 300 mg and clopidogrel 300 mg orally, the levels of hs-CRP and IL-6 in patients' plasma were measured. The major adverse cardiovascular events (MACE) were followed up for 12 months after treatment. Results Among 182 patients with AMI, 78 patients (42.8%) were in the fast metabolism group (CYP2C19*1/*1), 65 patients (35.7%) in medium metabolism group (CYP2C19*1/*2, CYP2C19*1/*3), 39 patients (21.5%) in the slow metabolism group (CYP2C19*2/*2, CYP2C19*2/*3, CYP2C19*3/*3).Compared with the fast metabolism group, hs-CRP and IL-6 levels in the medium and slow metabolism group were significantly higher (P<0.05); compared with the medium metabolism group, hs-CRP and IL-6 levels in the slow metabolism group were significantly increased (P<0.05). CYP2C19 genotype was positively correlated with hs-CRP and IL-6 levels (r=0.163, 0.175,P<0.05). The incidences of MACE in the medium and slow metabolism groups were higher than that in the fast metabolism group (P<0.05). Conclusion CYP2C19 genotypes were associated with hs-CRP and IL-6 levels. Medium and slow metabolism types of CYP2C19 gene can activate the inflammatory response and affect the clinical prognosis of patients with AMI.

Key words: acute myocardial infarction, CYP2C19, hs-CRP, IL-6, prognosis

吴天源, 罗义, 吕磊, 谭文亮, 孙少喜. CYP2C19基因多态性与急性心肌梗死患者炎症指标、临床预后的相关性[J]. 广州医药, 2022, 53(1): 1-5.

WU Tianyuan, LUO Yi, LV Lei, TAN Wenliang, SUN Shaoxi. Association of CYP2C19 gene polymorphism with inflammatory indexes and prognosis in patients with acute myocardial infarction[J]. Guangzhou Medical Journal, 2022, 53(1): 1-5.

参考文献

[1] RENAN S,ERICK H,SISKA S,et al.Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI)[J].Pharmacol Res Perspect,2021,9(2):1-8.
[2] CHA J J,LIM D S.Precision antiplatelet therapy for CYP2C19 genotype variants for achieving better clinical outcomes[J].JACC Cardiovasc Interv,2021,14(13):1500-1501.
[3] GAO Y,LOU Y,LIU Y,et al.The relationship between residual cholesterol risk and plaque characteristics in patients with acute coronary syndrome: Insights from an optical coherence tomography study[J].Atherosclerosis,2021,3(17):10-15.
[4] NADER S,KAMRAN M,AMIN H,et al.The effect of polymorphisms (174G> C and 572C> G) on the Interleukin-6 gene in coronary artery disease: a systematic review and meta-analysis[J].Genes Environ,2021,43(1):1.
[5] 吴铮,李文铮,王长华,等.CYP2C19基因多态性与PCI术后氯吡格雷治疗患者血小板功能、炎性指标及病情转归的相关性[J].疑难病杂志,2019,18(8):770-774.
[6] SCOTT S A,SANGKUHL K,SHULDINER A R,et al.TPharmGKB summary:very important pharmacogene information for cytochrome P450,family 2,subfamily C,polypeptide 19[J].Pharmacogenet Genomics,2012,22(2):159-165.
[7] 吴天源,李韶南,罗义,等.CYP2C19中代谢型急性冠脉综合征患者PCI术后支架内再狭窄的影响因素分析[J].中国心血管病研究,2017,15(12):1098-1101.
[8] FELIX R,LIZETH M,YADIRA X,et al.Association of CYP2C19*2 polymorphism with clopidogrel resistance among patients with high cardiovascular risk in Northeastern Mexico[J].Arch Cardiol Mex,2021,89(4):324-329.
[9] RIM C,KHADIJA M,MIRIAM B,et al.Response to clopidogrel and of the cytochrome CYP2C19 gene polymorphism[J].Tunis Med,2018,96(3):209-218.
[10] 郭元元,王丽英,张宇,等.冠心病患者CYP2C19基因多态性及临床不良事件发生与氯吡格雷抵抗的关系[J].检验医学与临床,2021,18(8):1054-1058.
[11] ALEXANDER P,KLAUS K,JULIAN M,et al.Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort[J].Clin Res Cardiol,2020,109(3):315-323.
[12] KASPAR B,ANNE K A,SINDRE W,et al.Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction[J].JAM Coll Cardiol,2021,77(15):1845-1855.
[13] TAN S Y,WAN X A,MICHAEL W,et al.CYP2C19 phenotype in South-East Asian Acute Coronary Syndrome patients and impact on major adverse cardiovascular events[J].J Clin Pharm Ther,2020,45(1):52-58.
[14] 吕磊,谭文亮,吴天源,等.急性冠脉综合征患者基因分型对血小板聚集率影响的研究[J].广州医药,2016,47(5):20-23.

[1]	陶豫东. 益生菌结合肠内营养干预纠正缺血性急性脑卒中患者肠道菌落紊乱的作用及对其预后的影响[J]. 广州医药, 2022, 53(1): 109-113.
[2]	肖驰, 周雪, 徐丹, 杨美英, 费晶, 巩平. SNCG在卵巢癌中的表达及其临床意义[J]. 广州医药, 2021, 52(5): 1-7.
[3]	古嘉基, 连泳欣, 丘福满. m6A甲基化基因风险评估模型在卵巢癌预后的临床意义[J]. 广州医药, 2021, 52(3): 1-8.
[4]	谢艳林, 董燕, 柳建华. 经胸超声心动图在Stanford A型主动脉夹层的诊断及预后评估中的价值[J]. 广州医药, 2021, 52(3): 36-40.
[5]	罗水妹, 黄颂平, 许白兰, 沈冰寒. 肺癌并发肺栓塞的危险因素及预后分析[J]. 广州医药, 2021, 52(2): 40-45.
[6]	陈希妍, 张建新, 牛丽丹, 孔令宇, 杨飞云, 石金河. 氯吡格雷联合低分子肝素对老年心肌梗死患者血清血脂及炎性因子的影响[J]. 广州医药, 2021, 52(2): 46-49.
[7]	岑昕贝, 凌济忠, 万跃平, 万颂, 华伟, 江敏耀, 习明. NR3C1表达与前列腺癌生化复发的相关性研究[J]. 广州医药, 2020, 51(4): 22-27.
[8]	刘霞, 方喜生, 翁成荫, 伍勇, 毛海波, 李宝秀, 王丽娜, 刘国龙. 原发性肝癌患者循环肿瘤细胞检测及其与术后复发转移的关系[J]. 广州医药, 2020, 51(2): 36-39.
[9]	李赟, 李勇, 巩平, 李小英, 李娜. 中性粒细胞与淋巴细胞比值在晚期不可切除结直肠癌患者化疗疗效及预后的意义[J]. 广州医药, 2020, 51(1): 59-65.
[10]	林颖欣, 庞丹梅, 胡倩, 段海波, 李财枝. D-二聚体在女性恶性肿瘤病情监测中的应用价值[J]. 广州医药, 2019, 50(2): 28-33.
[11]	张艳芳, 周洁, 杨宜帆, 殷思诺, 王丽. 372例老年冠脉支架植入患者临床特征及预后分析[J]. 广州医药, 2019, 50(2): 85-87.
[12]	林武周. 血清ApoA-1浓度在食管鳞状上皮细胞癌预后的价值[J]. 广州医药, 2019, 50(2): 113-115.
[13]	庄宇, 吕志芬, 陈宇航, 辛盼盼, 王志文, 谭志明. 难治性痛风30例临床治疗[J]. 广州医药, 2019, 50(1): 89-93.
[14]	黄斌, 徐靖, 曹拓. 急性脑出血并发高钠血症的原因及预后情况分析[J]. 广州医药, 2019, 50(1): 97-99.
[15]	叶飘, 雷晓明. 入院首次中性粒细胞/淋巴细胞比值与急性心肌梗死患者院内主要不良心血管事件发生的相关性研究[J]. 广州医药, 2018, 49(5): 13-17.